Incorporation of Epstein-Barr viral variation implicates significance of LMP1 in survival prediction and prognostic subgrouping in Burkitt lymphoma

Isaac E. Kim, Cliff I. Oduor, Julian Stamp, Micah A. Luftig, Ann M. Moormann, Lorin Crawford, Jeffrey A. BaileybioRxiv 2024 · DOI

TL;DR

This study reveals that specific variations within the Epstein-Barr virus (EBV), particularly in the LMP1 gene, are significantly associated with patient survival in Burkitt lymphoma (BL). By integrating EBV variants, human driver genes, and clinical factors, the researchers developed a predictive model and identified three distinct prognostic subgroups, offering new avenues for personalized treatment strategies.

What Problem Does This Paper Address?

Burkitt lymphoma (BL) is an aggressive B-cell lymphoma with a significant impact on pediatric cancer cases, especially in equatorial Africa. While the Epstein-Barr virus (EBV) is known to play a role in BL development, the extent to which EBV's genetic variations influence patient outcomes, such as survival, has remained unclear. Traditional classifications of BL often rely on epidemiological subtypes, but recent research suggests that EBV's molecular characteristics might offer a more relevant basis for subtyping and predicting prognosis. This paper aims to bridge this knowledge gap by investigating the association between specific EBV genetic variations and patient survival in BL, and to leverage these findings for improved prognostic subgrouping.

Methods

The researchers employed a multi-faceted approach combining statistical modeling and bioinformatics. They utilized Least Absolute Shrinkage and Selection Operator (LASSO) regression and Bayesian variable selection models within a Cox proportional hazards framework. These methods are powerful for identifying key predictive features from high-dimensional data, like genetic variants and clinical information, especially when the number of features exceeds the number of samples. The study also involved:

  • Whole-genome sequencing (WGS) data analysis: Publicly available WGS data from EBV-positive BL patients was processed to identify EBV variants and human driver genes.
  • Variant calling and annotation: Standard bioinformatics pipelines were used for identifying and annotating genetic variations.
  • Survival analysis: Cox proportional hazards models were used to assess the association between identified features and patient survival time.
  • Prognostic subgrouping: Non-negative matrix factorization (NMF) was used to cluster patients into distinct prognostic subgroups based on the identified features.
  • Model performance evaluation: Harrell's concordance index (c-index) was used to measure the predictive accuracy of the developed models.

Datasets

The study utilized publicly available whole-genome sequencing (WGS) data from 130 EBV-positive Burkitt lymphoma (BL) patients. These datasets were sourced from:

  • The Burkitt Lymphoma Genome Sequencing Project (BLGSP), accessed via the Genomic Data Commons (GDC) Data Portal (Project ID: CGCI-BLGSP, dbGaP Study Accession: phs000235).
  • Publicly available samples from Panea et al., accessed via the European Genome-Phenome Archive (Accession Number: EGAD00001005781).

The BLGSP samples originated from patients in Uganda, the United States, France, Canada, and Brazil. The Panea et al. samples were from patients in Kenya. The study also incorporated human somatic mutation data for recurrently mutated genes (driver genes) from these same sources.

Key Insights and Ideas

  • LMP1 is a key player: Specific variations within the LMP1 gene of EBV are strongly associated with patient survival in Burkitt lymphoma, suggesting its critical role in disease progression and outcome.
  • Beyond EBV type: While EBV type (1 vs. 2) has been studied, this research highlights that specific variants within EBV genes, particularly LMP1, are more predictive of survival than the overall EBV type.
  • Socioeconomic factors matter: Country income level emerged as the strongest individual predictor of survival, likely serving as a proxy for access to healthcare and quality of treatment, underscoring the interplay between biological and social determinants of health.
  • Interactions are crucial: The best survival prediction models were achieved when considering the combined effects of EBV variants, human driver genes, and clinical features, indicating complex interactions that influence patient outcomes.
  • New prognostic subgroups: The study successfully defined three distinct prognostic subgroups with differential survival rates, offering a more refined way to stratify patients and potentially guide treatment decisions.

Key Results

  • 22 EBV variants identified: The study identified 22 EBV variants, including seven within the LMP1 gene, that were most associated with patient survival time.
  • LMP1 variants' significance: Several LMP1 variants, such as H101Q, I152L, G212A, and G331Q, were found to be significantly associated with patient survival, with some showing strong hazard ratios. For example, H101Q had an adjusted hazard ratio of 10.94.
  • Country income level's impact: Country income level was the most significant individual feature, with a hazard ratio of 12.10, highlighting its critical role in survival. Patients from low-middle-income countries had a median survival of 1.9 years, compared to high-income countries with >50% survival.
  • Predictive model performance: The most comprehensive model, incorporating EBV variants, driver genes, and country income level, achieved the highest testing concordance index (c-index) of 0.76, indicating strong predictive power.
  • Three prognostic subgroups: The analysis defined three prognostic subgroups with significantly different survival rates (p=0.028), with Subgroup 1 showing the best survival, followed by Subgroup 2, and then Subgroup 3. These subgroups were characterized by distinct combinations of EBV variants and driver genes.

Limitations and Future Work

  • Sample size: The study acknowledges its main limitation is the relatively small sample size (130 EBV-positive BL samples), with a majority originating from Africa and South America. The authors note that their variable selection models were designed to mitigate this limitation.
  • Validation: The authors emphasize the need for validation of these findings on larger patient cohorts as they become available.
  • Functional studies: While the study identifies significant EBV variants, future work could delve into the functional mechanisms by which these variants influence BL pathogenesis and patient survival.
  • Interactions: Further exploration of the complex interactions between EBV variants, driver genes, and clinical factors could lead to a more comprehensive understanding of BL biology and improved therapeutic strategies.
  • Biomarker development: The identified EBV variants, particularly those in LMP1, are proposed as potential predictive biomarker candidates for future studies.

Summary updated

Abstract

ABSTRACT While Epstein-Barr virus (EBV) plays a role in Burkitt lymphoma (BL) tumorigenesis, it is unclear if EBV genetic variation impacts clinical outcomes. From 130 publicly available whole-genome tumor sequences of EBV-positive BL patients, we used least absolute shrinkage and selection operator (LASSO) regression and Bayesian variable selection models within a Cox proportional hazards framework to select the top EBV variants, putative driver genes, and clinical features associated with patient survival time. These features were incorporated into survival prediction and prognostic subgrouping models. Our model yielded 22 EBV variants including seven in LMP1 as most associated with patient survival time. Using the top EBV variants, driver genes, and clinical features, we defined three prognostic subgroups that demonstrated differential survival rates, laying the foundation for incorporating EBV variants such as those in LMP1 as predictive biomarker candidates in future studies.
BibTeX
@misc{kim2024incorporation,
  author = {Isaac E. Kim and Cliff I. Oduor and Julian Stamp and Micah A. Luftig and Ann M. Moormann and Lorin Crawford and Jeffrey A. Bailey and Jeffrey A. Bailey},
  title = {{Incorporation of Epstein-Barr viral variation implicates significance of LMP1 in survival prediction and prognostic subgrouping in Burkitt lymphoma}},
  year = {2024},
  doi = {10.1101/2024.05.03.592343},
  howpublished = {bioRxiv},
}

Loading related content...

Figure